We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





First-Ever SARS-CoV-2 Antibody Test Indicates Whether Patients Require COVID-19 Booster

By LabMedica International staff writers
Posted on 23 Jun 2022
Print article
Image: PictArray SARS-CoV-2 Antibody Test has received CE Mark (Photo courtesy of Pictor)
Image: PictArray SARS-CoV-2 Antibody Test has received CE Mark (Photo courtesy of Pictor)

The COVID-19 pandemic remains a healthcare concern as new strains of the virus have emerged. Now, a first-of-its-kind test enables personalized COVID-19 assessments by detecting if a patient has antibodies from a previous infection of SARS-CoV-2 or from vaccination alone.

The PictArray SARS-CoV-2 IgG enzyme-linked immunosorbent assay (ELISA) antibody test from Pictor Limited (Auckland, New Zealand) detects if a person has antibodies from a previous SARS-CoV-2 infection (from spike protein (SP) and nucleocapsid protein (NP) antibodies) or from COVID-19 vaccination alone (SP antibodies only). The test also indicates whether at-risk patients have failed to mount a detectable antibody response despite vaccination or infection (SP and NP negative).

Pictor has received confirmation of CE registration for its PictArray SARS-CoV-2 IgG ELISA antibody test as per In Vitro Diagnostic Directive (IVDD) regulations, allowing it to market the COVID-19 antibody test in Europe and gain regulatory approval in Southeast Asia.

“Receiving CE registration enables Pictor to establish a footprint with partner laboratories and research bodies within Europe which is an important market for us,” said Howard Moore, CEO of Pictor. “Our recent successful funding round means we are well equipped to support market development and launches within the European Economic Area while continuing existing work across ANZ, the U.S., India and Southeast Asia.”

“As we learn more about COVID-19, the separate detection of SP and NP will enable a more precise assessment of a patient’s immunity against SARS-CoV-2 and help guide any associated clinical interventions whilst also informing wider public health measures when mass serosurveys are conducted,” added Pictor’s Chief Medical Officer Tadd Lazarus, MD.

Related Links:
Pictor Limited 

New
Gold Supplier
SARS-CoV-2 Assay
INgezim COVID 19 SPIKE CROM
New
COL-R Assay
CHROMagar COL-APSE
New
Isothermal Microfluidic Chip Analyzer
CapitalBio RTisochip
New
Gold Supplier
Microplate-Strip Washer
Wellwash Versa

Print article

Channels

Molecular Diagnostics

view channel
Image: A new blood test could noninvasively and inexpensively detect colorectal cancer (Photo courtesy of Pexels)

Novel Blood Test Could Detect Early-Onset Colorectal Cancer

Colorectal cancer is the fourth most common cancer, according to the U.S. Centers for Disease Control and Prevention. The rate of colon or rectal cancers in people younger than 50 years old has been on... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.